nuclear oculomotor paralysis
ORPHA: 1009321 Treatment Available
Overview
human disease
Available Treatments (1)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Pyridostigmine | Tablets 60mg; Extended-release tablets 180mg; Syrup 60mg/5mL | FDA Approved | 8 | 7d |
Classification & Codes
Orphanet Code
ORPHA:100932nuclear oculomotor paralysis
| Orphanet | ORPHA:100932 |
| Treatments | 1 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO